BACKGROUND: Hypertension, hyperlipidemia, and diabetes are among the most prevalent and costly chronic health conditions affecting the U.S. population. Prescription treatments for these conditions are of critical importance to the health of patients, yet suboptimal adherence to prescription treatments for these conditions is not uncommon. While monthly prescription restriction has become a commonly used mechanism to reduce medication utilization, little is known about the effect of this policy on patients with hypertension, hyperlipidemia, or diabetes.
• Hypertension, hyperlipidemia, and diabetes are among the most prevalent and costly chronic health conditions affecting the U.S. population. Approximately one-third of U.S. adults aged 20 years or older have hypertension, one-sixth have hyperlipidemia, and one-tenth have diabetes. However, it was reported that 30% of patients with hypertension, 52% of patients with hyperlipidemia, and 16% of patients with diabetes receive no treatment for their conditions. • Low adherence to prescription treatments for these conditions has been shown to be associated with adverse outcomes, including higher risk of cardiovascular events and mortality, higher rate of inpatient admissions and emergency room visits, and higher total treatment costs.
• Evaluations of a prescription limit in 1982 in the New Hampshire
Medicaid program showed a significant drop in medication use immediately after policy implementation as well as a statistically significant increase in nursing home and hospital admissions among the mentally ill and elderly Medicaid populations.
What is already known about this subject
• This retrospective study examines whether the implementation of a prescription cap affects medication persistence among patients in Louisiana (LA, policy state) in comparison with Indiana (IN, comparison state that did not implement a cap on prescriptions) for treatments for hypertension, hyperlipidemia, or diabetes using Medicaid claims data from 2001-2003. • No differences in persistence were found before the policy implementation between LA and IN for any of the 3 chronic conditions. After policy implementation, patients with hyperlipidemia in LA were 1.13 (95% CI = 1.02-1.25; P < 0.05) times more likely to discontinue their treatments as their IN counterparts, while no significant differences were observed in the hypertension or diabetes cohorts (P > 0.05 for all other groups).
• Although inconclusive, this study suggests a potential for disruptions in medication persistency resulting from these policies.
Policy makers implementing restrictive policies should monitor closely for potential disruptions in patient care that might result following policy adoption.
increase in nursing home admissions (hazard ratio [HR] = 1.8, 95% confidence interval [CI] = 1.2-2.6) among chronically ill Medicaid beneficiaries who were aged 60 or older and a significant increase in hospital admissions (relative risk [RR] = 1.2, 95% CI = 0.8-1.6) were observed among patients who took 3 or more prescriptions at baseline. 24, 27 In a related study, restricting patients in the Mississippi Medicaid program to 5 prescriptions per month without prior authorization in 2002 resulted in lower adherence to antipsychotic medications. 22 However, this policy was enacted alongside increased copayments and other policies that made it difficult to isolate the effect of the monthly prescription cap policy. 22 The current study examines a monthly prescription limit implemented in the Louisiana Medicaid program. The policy began on March 3, 2003 , and limited patients to 8 prescription fills per month. 30 Patients who were younger than 21 years of age, who lived in a long-term care facility, or who were pregnant were exempted from this policy. Patients using more than 8 prescriptions could be exempted from the policy if they had a "medically necessary" condition and completed a prior authorization (PA) process. Physicians were required to provide evidence of a medically necessary exemption including the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis codes for medications exceeding the 8-prescription limit. After receiving the PA requirement, a pharmacist could then dispense the medications required.
Despite the increasing use of prescription caps in state Medicaid programs, there exists limited information about the effect of caps on health outcomes and medication adherence. This study examined whether the implementation of a prescription cap affected medication persistence of treatments for hypertension, hyperlipidemia, and diabetes. Understanding whether patients with chronic conditions may be adversely affected by the policy will help decision makers better design health policies under Medicaid or managed care settings. 3, 4 Depending on the population, the average costs per patient for hyperlipidemia ranged from $6,376 to $10,654 in 2007 and 2008. 5, 6 Prescription treatments for these conditions are critically important in the management of these conditions. However, studies suggest that approximately 30% of patients with hypertension, 52% of patients with hyperlipidemia, and 16% of patients with diabetes receive no pharmacological treatment for their conditions. [1] [2] [3] Adherence to medications for these conditions has been shown to be suboptimal, which reduces their potential for effectiveness. Rates of medication adherence have been estimated at 72%, 55%, and 65% for patients with hypertension, hyperlipidemia, and diabetes, respectively. [7] [8] [9] Low adherence to prescription treatments for these conditions has significant consequences for patient outcomes. Adherence to cardioprotective medications has been shown to be associated with a 48% reduction in all-cause mortality, 10 as well as lower total medical costs and hospitalization rates.
■■

11
In addition, studies have shown that patients with medication possession ratio (MPR) or proportion of days covered (PDC) ≥ 0.8 using antihypertensive drugs had lower risk of cardiovascular events, hospitalization, and emergency room visits as well as lower health care costs. [12] [13] [14] [15] Compared with patients whose MPR or PDC < 0.8, patients who were more adherent to statins had a 19% to 26% reduction in the risk of cardiovascular events 16, 17 and a 25% reduction in the risk of mortality. 18 Better adherence, defined as PDC ≥ 0.8, to antidiabetic drugs was similarly found to be associated with fewer emergency room visits (incidence rate ratio [IRR]:0.679-0.80; P < 0.05), a 2.7%-4.0% lower rate of complications, and 18 fewer shortterm disability days. 19 Predictors of nonadherence, which have been cited in the clinical literature, include the cost of treatment, increasing copayments for prescriptions, and administrative barriers to adherence. [20] [21] However, few studies have examined the effect of a monthly prescription limit on medication use, [21] [22] [23] [24] [25] [26] [27] [28] which has become an increasingly common cost reduction mechanism in state Medicaid programs. 29 Evaluations of a prescription limit in 1982 that restricted the number of drugs reimbursable to patients in the New Hampshire Medicaid program to 3 prescriptions per month showed a significant drop in medication use immediately after policy implementation. 23, 25, 26 Similar results were found in another study, which showed that New Hampshire's 3-drug monthly limit was associated with a decrease in cardiovascular medication use. 23 In addition, an for LA and IN Medicaid programs, IN did not appear to have any significant changes to its prescription policies during the period observed. Patients were included if they had at least 1 inpatient or 2 outpatient diagnoses of any of the 3 major conditions (ICD-9-CM diagnosis codes for essential hypertension: 401, disorders of lipoid metabolism: 272, or diabetes mellitus: 250) at any time during the 3-year study period. The 3 chronic condition groups were not mutually exclusive, and patients with more than 1 condition could be included in more than 1 cohort. In addition, patients were required to have at least 1 prescription claim for the 3 major conditions:
Study Design and Samples
• Hypertension: calcium channel blocker, angiotensin-converting enzyme inhibitors, beta blockers, alpha-beta blockers, and diuretics • Hyperlipidemia: antihyperlipidemic drugs • Diabetes: oral antidiabetic agents and insulins. Combination treatments were not included in this study, since no combination drugs were available during the study period (2001) (2002) (2003) .
To fully capture patients' medication utilization records, we excluded patients who did not have full Medicaid benefits, had private insurance coverage during 2001 to 2003 (i.e., number of months covered by private insurance > 0), had a long-term care claim, or had missing race information. Patients who had organ transplantation (ICD-9-CM: V42.x), pregnancy (ICD-9-CM: V22.x, V23.x), or human immunodeficiency virus (HIV; ICD-9-CM: 42.x) were excluded because they could be exempted from the prescription-limit policy.
We next identified incident cohorts (i.e., new users) representing pre-policy and policy period cohorts using a design described in Figure 1 . An enrollment period was defined as 6 months prior to both the pre-policy (March 2002) and policy period (March 2003) of observation, and each patient was assigned an index date as the first prescription filled of an oral agent during the enrollment period. To be qualified as a new user, a patient was required to be free of the specified drug classes for at least 180 days before the index date. For example, a patient with diabetes who received metformin during followup was required to have no claims for antidiabetic drugs during the pre-index period. Although insulin was classified as one of the antidiabetic treatments in the inclusion criteria to capture patients with diabetes comprehensively, patients who were on insulin only (without any use of oral antidiabetic drugs during the follow-up period) were excluded from the sample due to the difficulty of capturing medication persistence of injectable agents in claims data.
All patients were followed from the policy effective date (March 3, 2003) or 1 year before the policy was implemented (March 3, 2002) until medication discontinuation or the end of the pre-policy or policy period year (year of 2002 for the prepolicy group and year of 2003 for the policy group). A total of 6 incident cohorts were constructed from patients with each of the 3 chronic conditions in 2 states (LA and IN; Figure 1) . IN served as a control group to compare the effect of the policy in LA and did not use a prescription cap during the observation period in this study.
After applying the inclusion/exclusion criteria, we identified 4,809 and 3,129 patients with hypertension; 2,485 and 2,490 patients with hyperlipidemia; and 1,821 and 1,602 patients with diabetes in LA and IN, respectively ( Figure 2 ). There were 14,615 unique patients in the final sample, and 13,041 (89.2%) of them had only 1 condition; 1,427 (9.8%) of them had 2 conditions; and 147 (1.0%) of them had all 3 conditions.
Dependent and Independent Variables
The outcome of this study, medication persistence, was defined as a gap greater than 30 days in treatment. Using prescription fill date and days' supply, we checked whether a patient had medications on hand for a specified treatment class (i.e., antihypertensive, antihyperlipidemia, or antidiabetic drugs) for each day during the follow-up period. Patients without medication available for more than 30 consecutive days were considered as having discontinuation of therapy. A gap was defined as a period when patients discontinued all of their medications for the study condition. For example, patients who used 2 separate hypertension drugs needed to stop both hypertension drugs for more than 30 days to be considered as having a gap. Because of the complexity of insulin regimens, insulin was not taken into consideration for the persistence measure due to difficulty in measuring persistence of insulin accurately.
Patients who were on insulin treatment only were excluded from the study sample, and patients who switched from an oral antidiabetic agent to insulin were censored at the date of switch.
The key independent variable was a state indicator (LA vs. IN) where LA was the policy state and IN was the comparison state. Other control variables were age in 2001, gender (male vs. female), race (white vs. nonwhite), and whether a patient lived in a metropolitan statistical area (MSA). According to the U.S. Census Bureau, an MSA is defined as a region containing 50,000 or more population, which was used to define an urban area in this study. 31 Patient Characteristics for the Pre-and Post-Policy Cohorts diabetes group). However, the differences in medication persistence during the pre-policy period became insignificant after adjusting for covariates. During the post-policy period, the adjusted results indicated that patients with hyperlipidemia in LA were 1.13 times more likely to discontinue their medication treatment than patients in IN (HR = 1.13, 95% CI = 1.02-1.25; P = 0.024). No significant difference was found for patients with hypertension or diabetes between the 2 states in the post-policy period adjusted results. Complete outputs from the regression models for hypertension, hyperlipidemia, and diabetes cohorts are shown in appendices A-1, A-2, and A-3. Table 3 shows the results of the sensitivity analysis for patients who used 8 or more prescriptions during the prepolicy period. The sample for the sensitivity analysis included 559 and 923 patients with hypertension, 445 and 783 patients with hyperlipidemia, and 418 and 665 patients with diabetes in LA and IN, respectively. Similar to our main analysis, the adjusted results of the sensitivity analysis did not show any effect of the monthly prescription restriction policy on patients' persistence for antihypertensive and antidiabetic drugs (P > 0.05 for both groups in the pre-and post-policy periods). However, unlike the main analysis, the effect of the monthly prescription restriction policy on patients' persistence for hyperlipidemia treatment was insignificant in the sensitivity analysis (adjusted HR = 1.12, 95% CI = 0.86-1.46; P > 0.05). Sample attrition and baseline characteristics for the sensitivity analysis are presented in Appendix B.
■■ Discussion
This study evaluates the effect of a monthly prescription restriction policy on medication persistence in patients with diabetes, hypertension, or hyperlipidemia. After adjusting for all of the
Statistical Analysis
We began with descriptive statistics to summarize patient characteristics. T-tests and chi-square tests were used to compare continuous and categorical variables, respectively. Cox proportional hazard models were used to analyze the discontinuation rate in different disease cohorts between LA and IN, controlling for other covariates. In addition, a sensitivity analysis was conducted to evaluate the effect of the monthly restriction policy on medication persistence among patients using 8 or more prescriptions in any month during the preindex period. All analyses were stratified by the post-policy (2003) and pre-policy (2002) periods. SAS version 9.2 (Cary, NC) was used to perform the analyses. Statistical significance was determined a priori as P < 0.05 for 2-sided tests.
■■ Results
Patient characteristics for both the pre-and post-policy cohorts are reported in Table 1 . There were a number of differences between patients in LA and IN when examining the study cohorts, such as race, rural versus urban area residency, and comorbidity burden. Most notably, the LA population was consistently more likely to be nonwhite (61%-75% in LA vs. 12%-27% in IN; P < 0.05) across each of the conditions examined and less likely to live in rural areas (33%-38% in LA vs. 43%-44% in IN; P < 0.05). Table 2 presents the results from the Cox proportional hazard models. The unadjusted results showed that patients in LA had lower persistence than patients in IN for hypertension (HR = 1.18, 95% CI = 1.10-1.27; P < 0.01) and hyperlipidemia (HR = 1.22, 95% CI = 1.11-1.33; P < 0.01) in the prepolicy period and for all 3 conditions in the post-policy period (HR = 1.20, 95% CI = 1.12-1.30; P < 0.01 for the hypertension group; HR = 1.30, 95% CI = 1.20-1.42; P < 0.01 for the hyperlipidemia group; HR =1.20, 95% CI = 1.07-1.34; P < 0.05 for the 
Results from the Sensitivity Analysis for Patients Using 8 Prescriptions or More During the Pre-Policy Period
covariates, we did not find significant differences in medication persistence for patients with hypertension, hyperlipidemia, or diabetes during the pre-policy period. The adjusted results also suggested that the monthly prescription limit had no significant effect on medication persistence among patients with hypertension or diabetes, while a significantly lower persistence for antihyperlipidemia medications was observed during the post-policy period.
The null effect we observed among patients with hypertension or diabetes could be due to the multiple therapeutic classes used to treat hypertension or diabetes, which may make it easier for physicians and patients to find alternative regimens for their conditions. For example, patients with hypertension or diabetes could be on multiple drugs before the policy. They may discontinue 1 or 2 of their medications or reduce the frequency of dosing after the implementation of the policy to meet the 8 prescription restriction. 25, 33 Unlike patients with hypertension or diabetes, we found patients with hyperlipidemia were 13% more likely to discontinue their treatment after the implementation of the policy. Given that hyperlipidemia is an asymptomatic condition, patients may not feel the need for treatment and thus discontinue the therapy to meet the monthly prescription limit. 23 However, this is not a guarantee of policy effect because the confidence interval surrounding the hazard ratio for the postpolicy period is inclusive of the confidence interval surrounding the hazard ratio for the pre-policy period, which may be reflected by the fact that we did not observe a significant effect in the sensitivity analysis. On the other hand, the null finding in the sensitivity analysis may be the result of the relatively small sample size.
Limitations
There are several limitations of this study that should be considered when interpreting these results. First, our study results may not be generalizable to privately insured or uninsured populations. In addition, medication persistence was measured based on pharmacy claims, and it was assumed that prescriptions filled are actually taken. Moreover, information on medications obtained by self-payment or physician samples was not available in claims data. Although potential confounders were adjusted in this study, there could still be unmeasurable differences between LA and IN given the nonequivalent comparison group design. For example, a prior study has demonstrated that missing prescriptions paid out of pocket may lead to overestimation of the effect of the monthly prescription restriction policy. 30 Finally, it should be noted that this is a repeated crosssectional study, and we did not follow a single cohort over time. Time-to-event analysis was performed because the outcome of interest in this study was time to discontinuation. A time series approach would require following patients from the prepolicy to the post-policy period, while patients who "survived" to the post-policy period could be different from patients who discontinued their treatment before the policy implementation. Caution is needed when making causal inferences from this study. In addition to persistence, future research may further assess the effect of the monthly prescription restriction policy on health care costs.
■■ Conclusion
As Medicaid programs continue to struggle with controlling prescription spending, policies such as a monthly prescription limit may be used with greater frequency. Although inconclusive, this study suggests a potential for disruption in medication persistency resulting from these policies. Policy makers implementing restrictive policies should monitor closely for potential disruptions in patient care that might result following policy adoption. 
